Executive summary
The people with the most responsibility are often the last to seek help for a treatable condition. Across the general population the measured delay between the first symptoms of a mental health condition and the first treatment contact is roughly eleven years, and for some disorders it stretches past two decades. For senior professionals the barrier is not access or affordability, it is stigma, confidentiality, time and identity. This paper puts numbers on that delay, on what it costs an organization, and on the kind of confidential, senior appropriate care that shortens it.
Executives operate under sustained load while being the least able to be seen struggling, so a treatable condition is reframed as an operational problem and left to run.
Generic wellness programs and employer run EAPs rarely reach senior leaders, who avoid anything they believe could route information back to the organization.
Confidential, private pay care delivered by senior clinicians who work with high responsibility professionals, in session formats long enough to do real work.
Removing the confidentiality barrier turns a years long delay into an early intervention, before the cost becomes a vacancy.
The problemThe delay is the diagnosis nobody records§
Delay in seeking mental health care is neither rare nor small. Across US adults the average gap between the first symptoms of a mental health condition and the first treatment contact is about eleven years.1 The largest epidemiological study of the question found that among people who eventually get care, the median delay runs 6 to 8 years for mood disorders and 9 to 23 years for anxiety disorders.2 These are not the numbers of a population that refuses help. They are the numbers of a population that waits, often for a decade, while a treatable condition compounds. Mental illness itself is common, affecting more than one in five US adults in a given year,17 and roughly half of those affected receive no treatment at all.1 National surveys consistently place work related stress at the center of how employees describe their jobs.13
Among senior professionals the delay has a specific and expensive shape. The barrier is rarely money or availability. It is that admitting a mental health problem reads, to the person and to the culture around them, as conceding weakness. In one large survey 55 percent of CEOs said they had personally experienced a mental health issue, yet 81 percent agreed that companies still view someone with a mental health issue as weak or a burden.3 Consider a hypothetical scenario in which a division head notices six months of broken sleep and slipping decisions and files it under a hard quarter rather than a health problem. Nothing is written down, nothing is billed, and the clock on getting help never starts. The usual framing, that this is a private wellness matter, misses that its largest expression is a leadership seat quietly degrading in plain sight. Burnout itself is now classified as an occupational phenomenon rather than a personal failing.14
The most expensive symptom of executive burnout is the years spent deciding it is not burnout. CEREVITY clinical whitepaper, 2026
The evidenceWhat the research shows§
The delay can be measured rather than asserted, and the measurements are consistent across professions. What follows sets the general population figures beside what surveys report for the specific groups CEREVITY clinicians see most, and beside CEREVITY's own intake. The pattern CEREVITY describes in its work on why high performers wait to ask for help shows up clearly in the numbers.
55%
of CEOs report having personally experienced a mental health issue
Businessolver, 2024
4x
returned in better health and productivity for every $1 invested in treating depression and anxiety
WHO / Lancet Psychiatry, 2016
$210B
annual US economic burden of major depressive disorder among adults
Kessler et al., 2015
11 yrs
average delay between first symptoms and first treatment in the general population
Wang et al. / NAMI, 2005
Read together the figures establish one pattern. The people most able to pay for care are among the slowest to start it, and the reasons are structural rather than financial. The measured general population delay is roughly a decade,1 and even the professions that track their own wellbeing most closely show the same reluctance in a different accent. CEREVITY's own intake reflects a shorter but still substantial gap, a median of about 21 months between an executive first recognizing the problem and a first session (CEREVITY internal intake data, n=1,184, January 2024 to April 2026). That figure is an internal observation, not a peer reviewed statistic, and it is offered only to make one point: even the fast version of this delay is nearly two years of a leader operating impaired. The economics of closing it are not in question, since scaled up treatment for depression and anxiety returns about four dollars for every one invested.4 CEREVITY's account of why most CEOs report burnout traces the same reluctance from the inside.
| Population | Prevalence signal | Delay or documented barrier | Source |
|---|---|---|---|
| U.S. adults, baseline | 23.4% live with a mental illness | ~11 year median delay to first treatment | NAMI, 20241 |
| Mood disorders, onset to care | 88 to 94% are eventually treated | 6 to 8 year median delay | Wang et al., 20052 |
| Anxiety disorders, onset to care | 27 to 95% are eventually treated | 9 to 23 year median delay | Wang et al., 20052 |
| CEOs and senior executives | 55% report a mental health issue | 81% say firms view it as weakness | Businessolver, 20243 |
| Physicians | 40% would not seek formal care | Fear of licensing repercussions | Dyrbye et al., 20178 |
| Attorneys | 28% depression, 19% anxiety | Top barrier: confidentiality | Krill et al., 20169 |
| Founders and entrepreneurs | 49% report a lifetime condition | Isolation, identity fused to venture | Freeman et al., 201911 |
01, 03, 09, 11 Businessolver (2024); Freeman et al. (2019); Krill et al. (2016).
Baseline: National Alliance on Mental Illness (2024).
12 Deloitte and Workplace Intelligence (2022), survey of more than 2,100 executives and employees.
The frameworkA model you can name and own§
A delay that no one records is hard to interrupt, because it has no obvious moment of failure. The Deferral Cascade names the four stages an executive moves through between the first symptom and the first session. Its value is practical: each stage has a recognizable signal, and the earlier one is caught, the cheaper and more effective the intervention, because the whole point of the cascade is that the cost rises while the willingness to act stays flat until the end.
CEREVITY model
The Deferral Cascade
A four stage description of how a senior professional defers care from the first symptom to the first session. Each stage names a signal an employer, a partner, or the person themselves can recognize, and the cheapest window to act is always the earliest one.
Reframe
The first symptoms are recast as operational problems: a scheduling issue, a motivation issue, a discipline issue, anything but a clinical one. Because the problem is never named as health, the clock on seeking care never starts.
Absorb
The strain is carried in private. The executive compensates, protects the appearance of control, and tells no one, which delays both their own recognition and anyone else's.
Ration
Care is no longer refused, only postponed. A fixed weekly appointment loses every week to the calendar, so the earliest window that ever seems available is next quarter, indefinitely.
Forced hand
A health event, a crisis, or a resignation finally removes the choice. Care begins, but under the worst possible conditions and years later than it could have, when the condition is hardest to treat.
The model points to one decision. Because the cost curve and the willingness curve move in opposite directions, waiting for the problem to become undeniable guarantees paying for it at its most expensive. The intervention point is the earliest signal, and one of the clearest early signals is a leader whose decisions have started to slow, which is the target of CEREVITY's work on decision fatigue therapy.
SCHEMATIC Schematic, not measured data.
Conceptual model, CEREVITY. Curves are illustrative, not measured values.
By professionHow it presents across roles§
The delay looks different by profession, because the culture around admitting strain differs sharply from one field to the next. Three groups mark the range, and each is a population CEREVITY clinicians see rather than a single diagnosis.
Physicians
Physicians delay for a reason that is close to rational: seeking care can feel like a professional risk. In a study of 5,829 physicians, nearly 40 percent reported that they would be reluctant to seek formal medical care for a mental health condition because of concerns about the repercussions for their medical license.8 The reluctance is reinforced by licensing and credentialing questions that have historically treated a diagnosis as a red flag rather than a resolved matter.15 What CEREVITY clinicians see at the network level is a culture that reads needing help as a liability, so the strain is carried privately until it forces an error or a departure. The financial logic for a health system is unusually clear, because the cost of a single physician exit swamps the cost of the care that might have prevented it. That is precisely why confidentiality, and a route to care that does not run through the employer or the licensing file, matters more here than almost anywhere else. When those two conditions are met, the same physicians who would not walk into an employer program will start care, and they will start it earlier in the cascade rather than at the forced hand stage.
Individual therapy for physicians
Organizational ED physician burnout program vendor
Attorneys
For attorneys the delay is built into the culture and the billing model at once. The largest study of the profession, roughly 12,800 licensed lawyers, found that 28 percent were experiencing depression and 19 percent had symptoms of anxiety, with problem drinking at 21 percent, and it identified the two most common barriers to seeking help explicitly: fear of others finding out, and general concerns about confidentiality.9 Those are not vague worries; they are the same instincts that make a good litigator, turned against the person's own care.10 The profession's wellbeing has since become one of the most closely studied in any field.16 At the network level the pattern CEREVITY clinicians observe is a profession fluent in argument and reluctant to be a client, where admitting strain reads as conceding a case. For a firm the cost concentrates in its most leveraged people, the senior associates and partners whose departures are the most expensive to absorb, and whose delay is the hardest to detect because their output is defended longest. Care reaches this group only when it is genuinely confidential and built around unpredictable hours, which is why the delay shortens most when the confidentiality question is answered before anything else.
Individual therapy for attorneys
Organizational AmLaw 100 partner therapy benefit
Founders and entrepreneurs
Founders carry a version of the delay in which the identity and the enterprise are hard to separate. In Michael Freeman's research on 242 entrepreneurs, 49 percent reported a lifetime mental health condition and 72 percent reported being affected either directly or through their family, with elevated rates of depression and attention related conditions relative to a comparison group.11 The network level pattern is isolation dressed as drive. A founder is rarely able to be candid with a board, an investor, or a team that depends on their confidence, so the strain has almost nowhere to go and the deferral runs long. The cost to the people funding that founder is not abstract, because a leader stuck in the ration stage makes worse capital allocation and hiring decisions, and those choices compound across the whole company. For investors the case for supporting founder mental health is a portfolio protection argument as much as a human one, which is why it increasingly appears as a benefit offered at the fund level rather than left to each company to solve alone.
Individual therapy for founders
Organizational founder mental health partnership for VC firms
The stakesThe cost of inaction§
The cost of the delay is not abstract, and it does not wait for a resignation to appear. It shows up in three places a finance team already tracks: output, the compounding of an untreated condition, and eventually turnover.
The productivity tax of waiting
Most of the cost is invisible because it is presenteeism, not absence. Major depressive disorder alone carried a US economic burden of 210.5 billion dollars in 2010, and presenteeism, people at their desks but impaired, accounted for about 37 percent of that total, roughly 78.7 billion dollars.6 For a senior leader operating in the absorb or ration stage, that impairment concentrates in the decisions worth the most.
A condition that compounds
Delay is not neutral, because an untreated condition rarely holds still. The World Health Organization estimates that depression and anxiety cost the global economy about 1 trillion dollars a year in lost productivity, and that scaling up treatment returns roughly four dollars for every one invested.4 Every quarter a leader spends deferring care is a quarter of that return left on the table, and a condition that is measurably harder to treat once it reaches the forced hand stage.
The vacancy at the end
When the delay ends in an exit, the bill is largest and most visible. Turnover among senior leaders is expensive to absorb, and mental health is now a live retention factor: in a 2025 workplace survey half of US workers reported moderate to severe burnout, depression or anxiety, and 46 percent said they would worry about losing their job if they talked about their mental health at work.7 A benefit no one feels safe using does not prevent that exit.
04, 05 World Health Organization (2016); Chisholm et al. (2016), The Lancet Psychiatry.
The solutionWhat effective care looks like§
Good care for this population starts from a simple premise. The barrier is rarely access to therapy in general, it is access to therapy that fits a senior professional's constraints. That means genuine confidentiality, clinicians who are fluent in high responsibility work rather than surprised by it, and sessions long enough to do more than check in. It also means meeting the reality that the most senior people are the least likely to walk into a standard program, and the most likely to defer until a crisis forces the issue.
In practice this describes how CEREVITY is built. It is a nationwide network of independent licensed clinicians, matched to the person and delivered by secure video on a private pay basis that keeps the work confidential. Ongoing work happens in 50-minute therapy sessions, with 90-minute therapy sessions when a single hour is not enough to get anywhere.
For leaders facing an acute stretch, CEREVITY also offers 3-hour therapy intensives that compress a great deal of work into a single day. The private pay model is deliberate, with no insurance diagnosis code and no shared record, and it is explained in full in how CEREVITY approaches this work.
ImplementationHow to put it into practice§
Shortening the delay does not require a wellness overhaul. For most organizations it is four concrete steps, ordered from lowest effort to highest return.
- 01
Separate the barrier from the budget
Name the real reason senior people wait. It is not cost or availability, it is confidentiality, stigma and time. A program designed against those three barriers gets used; one designed against cost alone does not.
- 02
Offer confidential care outside the EAP
Executives avoid programs they believe route back to the organization. Provide a private pay, independent option with no shared record and no diagnosis code, so the people most at risk will actually start, and start earlier.
- 03
Match seniority to seniority
Senior leaders need clinicians fluent in high responsibility work. Match on experience, not just availability, and offer session formats long enough to do real work rather than a standing weekly slot the calendar will eat.
- 04
Catch the early stages, and measure it
Watch for the reframe and absorb signals, rising effort against flat output, shrinking recovery, slower decisions, and act then. Track utilization and retention so the investment can be judged against the vacancy it prevents.
RecommendationsWhere to start§
Clinical
Treat the delay as a clinical trajectory, not a mood
The deferral has recognizable stages and predictable early signals. Specialized executive burnout therapy is designed to intercept it before the forced hand stage, when it is both cheaper and more treatable.
Clinical
Answer the confidentiality question first
For senior professionals confidentiality is not a feature, it is the precondition for starting at all. Private pay, no diagnosis code, and no shared record are what convert an offered benefit into a used one, and what move care earlier in the cascade.
Structural
Build for the calendar, not against it
A fixed weekly appointment is the first thing an overloaded leader drops. Longer, less frequent formats, and clinicians who understand an executive's week, keep care from becoming the recurring casualty of a hard quarter.
Structural
Fund it against the vacancy, not the wellness line
Judged against a wellness budget, senior care looks discretionary. Judged against the cost of an unplanned executive exit, closing a two year delay pays for the program many times over. Even physicians, among the most reluctant to ask for help,8 start care when it is built for them, as CEREVITY's note on why physicians are the slowest to ask for help shows.
FAQCommon questions§
Why do executives wait so long to start therapy when they can clearly afford it?
Is a company EAP a confidential option for a senior leader?
What does the delay actually cost, compared with starting sooner?
How does private-pay billing work?
How is my privacy protected?
MethodologyHow this paper was built§
Methodology
This paper synthesizes published research on mental health treatment delay, prevalence, and economic cost, drawn from peer reviewed journals, large scale professional surveys, and government and institutional reports. Sources were identified through searches of PubMed, Google Scholar, and the publication libraries of the American Medical Association and Mayo Clinic Proceedings, the American Bar Association and Hazelden Betty Ford Foundation, the National Alliance on Mental Illness, the World Health Organization, Deloitte and Workplace Intelligence, Mind Share Partners, and the American Psychological Association, covering material published between 2005 and 2025, with priority given to the most recent available figures. The treatment delay figures are external and sourced. The eleven year average delay and the population prevalence and treatment rates come from the National Alliance on Mental Illness compilation of national survey data. The disorder specific delays, 6 to 8 years for mood disorders and 9 to 23 years for anxiety disorders, come from Wang and colleagues' analysis of the National Comorbidity Survey Replication, a household survey of 9,282 US adults. The professional prevalence and barrier figures come from named studies with stated samples: the 2024 Businessolver empathy study of more than 3,000 respondents, the Dyrbye and colleagues 2017 physician study of 5,829 physicians, the 2016 Krill and colleagues attorney study of roughly 12,800 lawyers conducted with the American Bar Association and Hazelden Betty Ford Foundation, Michael Freeman's 2019 study of 242 entrepreneurs, and the 2025 Mind Share Partners survey of 1,153 US employees. The cost estimates carry more uncertainty than the prevalence figures and should be read as models. The 210.5 billion dollar burden of major depressive disorder comes from Greenberg, Kessler and colleagues' 2015 analysis. The four to one return on treatment and the one trillion dollar global cost come from the World Health Organization and the associated Lancet Psychiatry return on investment analysis, and both are projections rather than measured outcomes. One figure in this paper is CEREVITY internal data and is labeled as such: a median of about 21 months between an executive first recognizing a problem and a first session, drawn from CEREVITY intake, n=1,184, January 2024 to April 2026. It is an internal observation of network level intake timing, not a peer reviewed measurement, and it is not directly comparable to the general population delay figures, which use symptom onset rather than problem recognition as their start point. Two further limitations should be explicit. First, prevalence and delay definitions differ across surveys, so figures are presented for magnitude rather than head to head ranking. Second, this paper contains no CEREVITY client outcome data; where CEREVITY clinical observation is referenced, it describes network level patterns clinicians report seeing.18
References
- 01National Alliance on Mental Illness. (2024). Mental Health By the Numbers. nami.org
- 02Wang, P. S., et al. (2005). Failure and Delay in Initial Treatment Contact After First Onset of Mental Disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. pubmed.ncbi.nlm.nih.gov
- 03Businessolver. (2024). 2024 State of Workplace Empathy Study: 55% of CEOs Say They've Experienced a Mental Health Issue. businessolver.com
- 04World Health Organization. (2016). Investing in treatment for depression and anxiety leads to fourfold return. who.int
- 05Chisholm, D., et al. (2016). Scaling-up treatment of depression and anxiety: a global return on investment analysis. The Lancet Psychiatry. thelancet.com)30024-4/fulltext
- 06Greenberg, P. E., Fournier, A. A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015). The Economic Burden of Adults With Major Depressive Disorder in the United States (2005 and 2010). The Journal of Clinical Psychiatry. psychiatrist.com
- 07Mind Share Partners. (2025). Mental Health at Work Report. mindsharepartners.org
- 08Dyrbye, L. N., et al. (2017). Medical Licensure Questions and Physician Reluctance to Seek Care for Mental Health Conditions. Mayo Clinic Proceedings. pubmed.ncbi.nlm.nih.gov
- 09Krill, P. R., Johnson, R., & Albert, L. (2016). The Prevalence of Substance Use and Other Mental Health Concerns Among American Attorneys. Journal of Addiction Medicine. journals.lww.com
- 10American Bar Association & Hazelden Betty Ford Foundation. (2016). First National Study on Attorney Substance Use and Mental Health Concerns. prnewswire.com
- 11Freeman, M. A., Johnson, S. L., Staudenmaier, P. J., & Zisser, M. R. (2019). The prevalence and co-occurrence of psychiatric conditions among entrepreneurs and their families. Small Business Economics. link.springer.com
- 12Deloitte & Workplace Intelligence. (2022). The C-suite's Role in Well-being. workplaceintelligence.com
- 13American Psychological Association. (2024). 2024 Work in America Survey. apa.org
- 14World Health Organization. (2019). Burn-out an occupational phenomenon: International Classification of Diseases. who.int
- 15Association of American Medical Colleges. (2022). Doctors forgo mental health care over concerns about licensing, stigma. aamc.org
- 16Harvard Law School Center on the Legal Profession. (2022). Studies on Well-Being in the Profession. clp.law.harvard.edu
- 17National Institute of Mental Health. (2024). Mental Illness. nimh.nih.gov
- 18McLean Hospital. (2023). The Silent Strain at the Top: Mental Health Among Executive Leadership. mcleanhospital.org
PhD, Licensed Psychologist
Dr. Grossman is a Licensed Psychologist with more than 15 years of clinical experience working with entrepreneurs, founders, senior executives, and high-responsibility professionals navigating burnout, anxiety, and depression. His work integrates cognitive behavioral therapy, acceptance and commitment therapy, behavioral activation, and schema-informed approaches calibrated to the working week his clients are actually living in. He sees clients via CEREVITY's nationwide telehealth network.
Talk to someone who gets it.
If this paper describes something you recognize, a confidential conversation is the next step. CEREVITY matches you to an independent licensed clinician who works with people in your position.
Schedule consultationPrivate-pay, telehealth, nationwide. Questions: (562) 295-6650
